Skip to main content

Allarity Therapeutics, Inc.

ALLR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001860657

No open-market purchases or sales by Allarity Therapeutics, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Allarity Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of ALLR: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders1011+1
Shares195.1K1.03M+838.1K (+429.6%)
Value$197.0K$1.63M+$1.44M (+728.5%)

New holders (7)

Institutions that held Allarity Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to ALLR in Q3 2025
InstitutionSharesValue% of portfolio
Private Advisor Group, LLC278,949$440.7K0.00%
Vanguard Group Inc246,708$389.8K0.00%
State Street Corp137,600$217.4K0.00%
Citadel Advisors LLC94,142$148.7K0.00%
Renaissance Technologies LLC66,186$104.6K0.00%
Northern Trust Corp43,626$68.9K0.00%
Two Sigma Investments, LP13,910$22.0K0.00%

Sold out (6)

Institutions that held Allarity Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of ALLR in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
XTX Topco Ltd50,950$51.5K
UBS Group AG47,984$48.5K
Jane Street Group, LLC26,365$26.6K
Squarepoint Ops LLC14,450$14.6K
Tower Research Capital LLC (TRC)3,073$3.10K
Citigroup Inc1,472$1.49K